News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Helix Biopharma (CC:HBP) Signs L-DOS47 Manufacturing Agreement With QSV Biologics, Ltd.



12/22/2005 12:34:41 PM

AURORA, ON, Dec. 22 /CNW/ - Helix BioPharma Corp. (Helix; TSX, FSE: "HBP") today announced that it has signed an agreement with Edmonton, Alberta-based QSV Biologics (QSV) to develop the cGMP manufacturing process for L-DOS47. "The signing of this agreement with QSV is a major step in the L-DOS47 program," said Dr. Donald Segal, President and CEO of Helix. "We believe QSV's high caliber personnel and facilities for biopharmaceutical manufacturing will accelerate the cGMP production of L-DOS47 for our upcoming preclinical and human clinical studies."

Read at Canada NewsWire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES